The S-1, PPM, and offering-memorandum risk factors that every cannabis fund and operator has been recycling since 2018 just got obsolete on a Wednesday. Cannabis was Schedule I when the language was written. Cannabis is — for state-medical-licensed activity — Schedule III now. The risk factors that started “Marijuana is a Schedule I controlled substance under federal law” need rewriting, and they need rewriting before your next data room goes out, your next PPM update closes, or your S-1 amendment gets reviewed by SEC staff.
This post is the Schedule III cannabis investor disclosure update. Eight critical risk factors that need new language post-Final Order, M&A diligence checklists that need updating, valuation models that need recalibrating, and the disclosure-package CTA at the end.
Why investor disclosure changed on April 22, 2026
Three structural reasons:
- Risk profile bifurcation. Pre-April 22, 2026, cannabis risk factors were uniform: federal illegality + Schedule I + 280E + banking + payments + DEA. Post-April 22, 2026, the risk profile bifurcates. State-medical-licensed activity sits in a materially different federal-risk lane than non-covered activity. Disclosure must distinguish.
- Valuation impact. The 280E disallowance was costing operators 20-50% of net income in additional federal tax. Schedule III recognition for covered activity changes the cash-flow model. EBITDA expansion is real and material. Investor disclosure must present the multiplier — and the conditions on it.
- Forward-looking statements. Treasury / IRS / FinCEN / DEA guidance is in motion. SEC’s standard “forward-looking statements” language needs updating to reflect Schedule III specifics.
The work is mechanical (update the language) plus substantive (recalibrate the model). Both must happen before your next disclosure event.
The 8 critical risk factor updates
Risk Factor 1 — Schedule I vs. Schedule III bifurcation
OLD: “Marijuana is a Schedule I controlled substance under federal law…”
NEW: “Marijuana is generally a Schedule I controlled substance under federal law. Pursuant to the DOJ/DEA Final Order effective April 22, 2026, FDA-approved marijuana products and marijuana subject to a qualifying state-issued medical marijuana license are placed in Schedule III. Schedule III treatment, where applicable, materially affects but does not eliminate federal regulatory risk. The Company [does/does not] hold a state medical marijuana license that qualifies under the Final Order. [Describe specifics.] Activity outside the Schedule III channel remains subject to Schedule I federal treatment.”
This is the foundational rewrite. Every subsequent risk factor builds on it.
Risk Factor 2 — Section 280E exposure
OLD: “Internal Revenue Code Section 280E disallows deductions for trafficking in Schedule I and II controlled substances, materially increasing the Company’s effective tax rate…”
NEW: “Internal Revenue Code Section 280E disallows deductions for trafficking in Schedule I and II controlled substances. For covered activity under Schedule III, Section 280E should not apply. Treasury and IRS announced on April 23, 2026 the intent to issue guidance addressing tax consequences, including potential retrospective relief and apportionment for mixed activity. The Company has [filed/intends to file/has not filed] protective claims for prior taxable years. Realization of any 280E relief depends on Treasury / IRS guidance, the scope of the Final Order surviving litigation, and the Company’s documentation of covered-activity allocation.”
Add specifics on the Company’s protective-claim filings, allocation methodology, and any Treasury guidance issued since the Final Order. See 280E Retrospective Relief for the underlying mechanics.
Risk Factor 3 — Banking and FinCEN
OLD: “Federal illegality of marijuana creates substantial banking risk. The Company maintains banking relationships only with banks willing to serve marijuana-related businesses, and those relationships may be terminated at any time…”
NEW: “FinCEN’s 2014 marijuana-related-business guidance remains in force, and BSA / SAR obligations continue to apply. The Final Order’s recognition of state-medical-licensed activity as Schedule III materially improves but does not eliminate banking risk. Account closures, SAR filings, and compliance-cost increases remain possible. The Company has [describe banking relationships, jurisdictional concentration, and compliance file status].”
Risk Factor 4 — Payment processing and card networks
OLD: “The Company is unable to accept major credit-card payments due to federal illegality of marijuana and card-network rules…”
NEW: “Major card networks (Visa, Mastercard, American Express, Discover) maintain rules that prohibit or restrict marijuana transactions. Network rules have not been updated to reflect the Schedule III recognition of state-medical-licensed activity. There is no guarantee networks will update rules in any specified period. The Company [does/does not] accept major card-network payments. Continued reliance on cash, ACH, and third-party payment facilitators introduces operational, compliance, and customer-experience risks.”
Risk Factor 5 — DEA registration and federal authorization
OLD: “The Company does not hold federal authorization to handle marijuana under the Controlled Substances Act…”
NEW: “The Final Order establishes an expedited DEA registration pathway for state medical marijuana licensees. DEA registration, where applicable, requires compliance with 21 C.F.R. Parts 1301, 1304, 1306, 1312, 1317, and 1318. The Company [intends to / has applied for / does not currently hold / is not eligible for] DEA registration. DEA may deny registration on any number of grounds. Registration imposes ongoing federal compliance obligations, security plan requirements, and records duties.”
See Federal Cannabis License: 10 Critical DEA Steps for the DEA registration playbook.
Risk Factor 6 — Litigation risk to the Final Order itself
NEW (no analog in pre-Final-Order disclosure): “The Final Order is subject to legal challenge. DOJ relied on 21 U.S.C. § 811(d)(1) treaty-control authority rather than the standard § 811(a) eight-factor analysis. Industry challengers, state attorneys general, and law-and-order plaintiffs may bring legal challenges. The Final Order may be remanded, narrowed, or invalidated in whole or in part. The Company’s position depends on the Final Order’s continued applicability.”
Risk Factor 7 — State licensing and OTC Endorsement dependency
NEW: “The Final Order’s Schedule III recognition applies only to marijuana subject to a qualifying state-issued medical marijuana license. The Company operates in [States]. State [Name(s)] [has / has not] adopted an OTC Therapeutic Cannabis Endorsement framework or equivalent program structure. In states without such a framework, Schedule III recognition for the Company’s activity may be unavailable. Future state legislative action [is / is not] anticipated; outcomes are uncertain.”
Risk Factor 8 — Federal interstate commerce and FDCA
NEW: “Schedule III status does not authorize interstate transport of cannabis or cannabis products. The Company complies with intrastate-only operating restrictions imposed by state law. The Final Order does not modify FDCA jurisdiction over drug claims, dosage forms, or product approval. Unauthorized drug-treatment claims by the Company in connection with cannabis products may expose the Company to FDCA enforcement risk.”
M&A diligence checklist updates
For target operators, diligence should now include:
- State medical marijuana license documentation. Issue dates, renewals, scope, endorsements. Confirm covered-activity status under the Final Order.
- Transaction-level medical-purpose records. Sample size sufficient to validate aggregate covered-activity claim. Quality of records affects 280E protective claim and banking file.
- OTC Therapeutic Endorsement compliance. State program participation, customer self-certification volume, consultant overlay implementation.
- Tax position analysis. 280E protective claims filed, allocation methodology documentation, prior-year amended returns or refund claims.
- Banking file. State medical endorsement, regulator-verifiable license status, expected-activity profile, anti-diversion controls.
- DEA registration status / readiness. Application status, security plan, federal-readiness file.
- Card-processing arrangements. Review for network-rule compliance, MID structure, chargeback rates, processor agreements.
- Pending federal litigation exposure. Any direct or indirect exposure to Final Order challenges, IRS audits, FinCEN inquiries, DEA inspections.
- State legislative trajectory. Pending OTC Endorsement legislation, regulator rule-making, ballot initiatives.
- Reps and warranties expansion. Schedule III-specific reps including license status, covered-activity status, compliance with state medical cannabis program, banking file completeness, tax positions.
For the M&A and valuation deep dives, see Cannabis M&A Under Schedule III and Cannabis Company Valuations Under Schedule III.
Valuation impact — the 280E multiplier
Pre-Schedule III, a typical state-licensed cannabis dispensary lost 20-50% of pre-tax income to the 280E deduction disallowance. Effective tax rates routinely exceeded 70-80%.
Post-Schedule III for covered activity, that disallowance — assuming Treasury guidance follows DOJ’s invitation — should not apply. The cash-flow recovery is the 280E multiplier.
Illustrative model (numbers for example only):
Metric
Pre-Schedule III
Post-Schedule III (Covered Activity)
Revenue
$20M
$20M
COGS
$8M (allowed via § 471)
$8M
Gross Profit
$12M
$12M
Operating Expenses
$7M (largely disallowed under 280E)
$7M (now deductible)
EBITDA
$5M
$5M
Federal Tax (illustrative)
~$3.4M (effective ~70%)
~$1M (effective ~21% C-corp)
Net Income
$1.6M
$4M
Net Income Multiple → EV
10x → $16M
10x → $40M
The valuation lift in this illustrative model is 2-3x for covered activity. Real numbers vary by capital structure, COGS allocation, and state-tax interaction. The point: investor disclosure that does not address the multiplier is leaving the upside undisclosed. Investor disclosure that does address the multiplier must include the conditions (Treasury guidance, license status, allocation methodology, litigation risk).
For cannabis funds and lenders
Update your fund offering documents:
- Investment thesis section. Add Schedule III recognition as a core thesis driver. Distinguish covered-activity portfolio companies from non-covered-activity portfolio companies. Set portfolio targets accordingly.
- Risk factors. Use the eight rewrites above.
- Use of proceeds. Allocate fund capital to operators with covered-activity status (or with credible OTC Endorsement adoption pathways in their state).
- LP communications. Issue an LP letter explaining the Schedule III moment, fund repositioning, and forward outlook.
- GP update / Form ADV (if applicable). Update the firm-level disclosure.
- Valuation policies. Update mark-to-market or fair-value methodologies to reflect 280E multiplier where applicable.
Lenders should similarly update credit policies, collateral assumptions (license values, including endorsement status), and covenant language (require operators to maintain endorsement / covered-activity status).
Schedule III Cannabis Investor Disclosure FAQ
Do I need to refile my S-1 or update my PPM immediately?
If your offering is currently in registration or distribution, yes — disclosure updates are likely required. Consult your securities counsel immediately. New offerings should incorporate the eight rewrites from outset.
Does Schedule III change SEC’s view of cannabis listings?
SEC has historically approved cannabis disclosure that addressed federal illegality. Schedule III for covered activity is a material disclosure update. SEC review of new filings post-April 2026 will likely focus on the bifurcated risk profile and 280E multiplier disclosure.
Are public-company cannabis disclosures going to look different now?
Materially. 10-K risk factors, 10-Q updates, and 8-K Item 8.01 disclosures around the Final Order are appropriate for public cannabis companies. Engage securities counsel before filing.
What should LPs in cannabis funds expect?
LP letter explaining the Schedule III moment and fund repositioning. Updated disclosures in next quarterly report. Possible amendment to fund offering documents if material to the fund’s investment program.
Does this affect cannabis SPAC structures?
Yes. Cannabis SPACs targeting state-licensed operators should incorporate the bifurcated disclosure and 280E multiplier into target evaluation, S-4 disclosure, and post-de-SPAC ongoing reporting.
How does this interact with state-licensed insider trading?
Insider trading rules apply normally. Material non-public information about state license status, OTC Endorsement adoption, DEA registration status, or Final Order litigation can be material to investors and must be disclosed appropriately.
Get the Investor / Lender Disclosure Package
The Investor / Lender Disclosure Package is built for cannabis funds, lenders, public-co counsel, and M&A buyers. Includes: full risk-factor rewrites, S-1 / PPM language, 10-K / 10-Q updates, Form ADV adjustments, M&A diligence checklists, valuation methodology memo, and ongoing-reporting templates.
Get the Investor Disclosure Package.
For the full hub: Schedule III Cannabis: The Operator, Lawyer & Investor Hub.
- 280E Retrospective Relief (Cluster 2)
- Cannabis M&A Under Schedule III (Cluster 12)
- State-by-State Schedule III Conversion Playbook (Cluster 8)
- Howard East corporate law — for entity-level disclosure work, S-1 review, M&A reps & warranties
- DOJ Final Order
- Treasury Press Release 4/23/2026
- Article + FAQPage
External ≥2
Cross-site ≥1
Schedule III Cannabis · Cannabis M&A · Federal Cannabis Legalization
cannabis investor disclosure · cannabis risk factors · Schedule III investor disclosure · cannabis M&A · cannabis valuation · cannabis fund disclosure · 280E multiplier · cannabis SPAC
Want the full Schedule III playbook?
This post is one cluster of The Schedule III Cannabis Hub, the operator, lawyer, and investor briefing on DOJ’s April 2026 Final Order.